Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
I Com Medical GmbH is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution path for the company's current intellectual property. The involvement of only 1 distinct art unit suggests that the pending innovation is specialized within a narrow technical field of medical or biological science.
The busiest examiner for the company is OLSON, ANDREA STEFFEL, who oversees 1 pending office action. Since the company's current activity is limited to 1 distinct examiner, the outcome of the prosecution depends on the specific interpretations and requirements of this individual. This lack of examiner diversity means that the applicant's current experience is shaped by a single point of contact at the patent office. For a practitioner, the focus remains on resolving the specific issues raised by the 1 distinct examiner for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001490 | HIGH MOLECULAR WEIGHT HYALURONIC ACID FOR USE IN THE TREATMENT OF CORNEAL NERVE DAMAGE OR LOSS | OLSON, ANDREA STEFFEL | 1693 | §103Other | Final Rejection | — | Pending | Dec 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial